MedTrace Logo

Study of NMS-1116354 in Advanced/Metastatic Solid Tumors

NCT01092052 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-09-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety profile of NMS-1116354, a CDC7 kinase inhibitor, in adult patients with advanced/metastatic solid tumors.

Conditions

  • Advanced/Metastatic Solid Tumors

Interventions

DRUG

NMS-1116354

Oral daily administration for 14 consecutive days followed by 7 days of rest

Sponsors & Collaborators

  • Nerviano Medical Sciences

    lead INDUSTRY

Principal Investigators

  • Jean-Charles Soria, MD · Institut Gustave-Roussy (IGR)

  • Stefania Crippa, Biotech D, PhD · Nerviano Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01092052 on ClinicalTrials.gov